Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1996-06-21
2000-02-01
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
4241851, 4241931, 435 71, 4353723, 435 723, 3503888, 3503871, 514 15, 436506, 5303881, A61K 3900, C12N 1585, C07K 1600
Patent
active
060199873
ABSTRACT:
Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
Engelhard, V., Curr. Opin. Immunol. 6:13-23, "Structure of peptides associated with MHC Class I molecules", 1994.
Rammensee et al., Annu. Rev. Immunol. 11:213-244, Peptides naturally presented by MHC Class I molecules, 1993.
Rammensee et al., Immunogenetics 41:178-228, "MHC ligands and peptide motifs: first listing", 1995.
Tanaka, et al., "Induction of Antitumor Cytotoxic T Lymphocytes With A MAGE-3 Encoded Synthetic Peptide Presented by Human Leukocytesntigen-24," Canc.Res. 57:4465-4468 (1997).
Traversari et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E", J. Exp. Med 176: 1453-1457 (11-92).
Celis et al., "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes", Proc. Natl. Acad. Sci. USA 91: 2105-2109 (Mar. 1994.
Coulie et al., "A New Gene Coding For A Differential Antigen Recognized By Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas", J. Exp. Med. 180: 35-42 (Jul., 1994) (Not Prior Art).
Engelhard et al., "Structure of Peptides Associated With Class I and Class II MHC Molecules", Ann. Rev. Immunol. 12: 181-207 (1994).
Ruppert et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules", Cell 74: 929-937 (Sep. 10, 1993).
Houbiers et al., "In Vitro Induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53", Eur. J. Immunol. 23: 2072-2077 (1993).
Townsend et al., "The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can be Defined With Short Synthetic Peptides", Cell 44: 959-968 (Mar. 28, 1986).
Bjorkman et al., "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens", Nature 329: 512-518 (Oct. 8, 1987).
Van der Bruggen et al., "A Gene Encoding an Antigenic Recognized by Cytolytic T Lymphocytes on a Human Melanoma", Science 254: 1643-1647 (1991).
Boon-Falleur Thierry
Fleischauer Katharina
Traversari Catia
van der Bruggen Pierre
Chan Christina Y.
Lubet Martha
Ludwig Institute for Cancer Research
LandOfFree
Isolated, MAGE-3 derived peptides which complex with HLA-A2 mole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated, MAGE-3 derived peptides which complex with HLA-A2 mole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated, MAGE-3 derived peptides which complex with HLA-A2 mole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-935272